MedPath

A retrospective study in clinical course of Heicobacter pylori eradication therapy

Not Applicable
Conditions
H.pylori infected patients
Registration Number
JPRN-UMIN000032351
Lead Sponsor
Asahikawa Medical University
Brief Summary

Vonoprazan-based triple therapy was effective as susceptibility-guided triple therapy for H. pylori eradication.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
427
Inclusion Criteria

Not provided

Exclusion Criteria

patient who refused the therapy

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary outcome is non-inferiority of vonoprazan-based therapy for other regimens including PPI-based therapy.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath